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A series of ureas was prepared by reacting mono- or di- isocyanates with 3-amino-1H-1,2,4-triazole
derivatives. The new carboxamides were investigated as activators of two human (h) carbonic anhy-
drases (CAs, EC 4.2.1.1), the physiologically relevant isoforms hCA I and II, considering the fact that they
have structural resemblance to histamine, a well-known CA activator. Highly effective activators were
detected in the series, with potency in the low nanomolar and subnanomolar range, depending on the
substitution pattern at the 1,2,4-triazole ring and the nature of the linker between the two heterocyclic
rings, in the case of the diureas. The most effective hCA II activator (KA of 0.05 nM) ever reported has been
evidenced in this study. Although CA activators do not have pharmacological applications for the
moment, in animal models it has been shown that they enhance cognition, making them interesting
for conditions in which CA activity is diminished, such as aging or Alzheimer’s disease.
 2017 Elsevier Ltd. All rights reserved.1. Introduction
The carbonic anhydrases (CAs, EC 4.2.1.1) represent a superfam-
ily of metalloenzymes, with seven different genetic families known
to date, the a-, b-, c-, d-, f-, g- and h-CAs, all of the which effi-
ciently catalyze the reaction between CO2 and water, with forma-
tion of bicarbonate and protons.1–4 The inhibition and activation of
CAs are well-understood processes: most types of classical inhibi-
tors bind to the metal center within the enzyme active site,5–11
whereas the activators bind at the entrance of the active site cavity
and participate in proton shuttling processes between the metal
ion – bound water molecule and the environment.12,13 This leads
to enhanced formation of the metal hydroxide, catalytically active
species of the enzyme. The most studied class is surely a-CAs,
which are expressed widespread in humans and mammals, and
is composed by 16 isoforms that also possess esterase or thioester-
ase activity.2 Aberrant expression or activation of some isoforms of
a-CAs is associated to a number of human diseases, among which
cancer is surely the most prominent.1,3 Accordingly, the design and
development of small molecules able to inhibit CAs functions
in vitro and in vivo has represented a valuable opportunity in drug
discovery.1,4 A number of CA inhibitors (CAIs) are available in thedrug market for the therapy of glaucoma,5 such as the sulfon-
amides dorzolamide, methazolamide and acetazolamide,1b,1c,6
this latter being the most widespread CAI used also with other
therapeutic indications such as diuretic and antiepileptic.6c
However, these drugs are pan-CAs inhibitors and the systemic
administration is generally associated to adverse off-target
effects. Nowadays the development of CAIs is facilitated by the
advances recorded in biotechnology, structural biology,
computational modeling and organic chemistry, which offer the
valuable opportunity to investigate multiple chemotypes as CAIs
and to characterize the atomic details of their interaction with
the target enzymes.1b,7
In recent years, particular attention and interest have been cap-
tured by the identification, structural characterization and under-
standing of the physiological and pharmacologic roles that CA
activators may play.12–14 Only in 1997 we reported the first X-
ray crystal structure of an activator bound to the human (h) CA iso-
form hCA II.12b This activator was histamine, and was found bound
at the entrance of the CA active site cavity, with the imidazole
moiety participating in shuttling protons between the active site
and the bulk solvent, thus acting as a second proton shuttle of
the enzyme in addition to His64, whereas the amino group from
the aminoethyl moiety of histamine did not participate in any
interaction with the enzyme active site. This was the reason why
many histamine derivatives in which the aliphatic amine was
chemically modified were thereafter investigated as CA activators
2 Y. Le Duc et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx(CAAs).12–14 Although CAAs do not have clinical applications for the
moment, it has been reported that some CAAs (such as phenylala-
nine or imidazole) administered to experimental animals may pro-
duce an important pharmacological enhancement of synaptic
efficacy, spatial learning and memory, proving that this class of rel-
atively unexplored enzyme modulators may have important appli-
cations in conditions in which learning and memory are impaired,
such as for example aging or Alzheimer’s disease.15 It has also been
reported that the levels of CA are significantly diminished in the
brain of patients affected by Alzheimer’s disease15c and these
facts strongly support the involvement of different brain CA
isozymes in cognitive functions.
2. Results and discussion
2.1. Drug design of the new CAAs
Histamine (HST), the first CAA for which the binding has been
revealed by using X-ray crystallography (in adduct with isoform
hCA II) has been used as lead compound.12b
Derivatives 1–14were prepared as shown in Scheme 1, incorpo-
rate 1,2,4-triazole instead of the imidazole moiety present in HST,
as well as amino or COOH moiety able to participate in proton
transfer processes.12–14
Derivatives with one heterocyclic ring (1–3) as well as deriva-
tives with two such moieties (4–14) were obtained, in order to
investigate a possible cooperativity effect between the two moi-
eties with proton transferring capacity. The other fragments pre-
sent in these molecules (moieties R and R0) are alkyl, alkylene,
cycloalkyl, aryl, etc., and were introduced in order to have different
linkers of variable length between the two heterocyclic rings (in 4–
14) as well as for modulating lipophilicity and potentially the
interaction with the enzyme active site (in all these derivatives).
An ureido linker connected the two fragments of these molecules
(the heterocycle and the lipophilic tails) since it was been reported
that such a moiety assures an appropriate degree of flexibility for
the modulator of activity bound within the CA active site.12–15
Compounds 1–14 were obtained by a routine chemistry, i.e., reac-
tion of isocyanates/di-isocyanates with the appropriate 1,2,4-tria-
zole derivative (Scheme 1). Compound 5 has been previously
reported.16 It forms stable helical pores in lipid bilayers. Experi-
mental assays revealed that the T-channel with the hydrated car-
bonyl and amine moieties pointing toward the T-channel center
and surrounding the transport direction, presents moderated
water permeability and large open ion-conductance states.N
N
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Scheme 1. Synthesis of compounds 1–
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The activator-binding site within the CA active cavity was a
rather controversial issue till 1997, when the first X-ray crystal
structure of an activator bound to CA II was reported, i.e., the
hCA II – histamine adduct.12b Thereafter, many other CA –
activator adducts were reported and investigated by high
resolution X-ray crystallography, being shown that they bind
within the same part of the active site, i.e., at its entrance.12 In this
way, through protonatable moieties found in their molecules they
participate to supplementary shuttling processes of protons
between the enzyme active site and the environment, facilitating
the formation of the zinc hydroxide, nucleophilic species of the
enzyme.
Surprisingly, in 2009 we have reported that coumarins, such as
derivative 15a (Scheme 2), a natural product isolated from an Aus-
tralian plant,17 act as CA inhibitors, but their binding site within
the CA enzyme cavity is the same as the activator binding site evi-
denced earlier (Fig. 1).12,17 In fact, the coumarin 15a is hydrolyzed
within the CA active site to the 2-hydroxy-cinnamic acid derivative
15b, which has been observed bound in the activator – binding
site, as illustrated in Fig. 1, where two CA activators adducts (his-
tamine and L-adrenaline) were superposed on the hCA II – cou-
marin X-ray crystal structure.17 Thus, the entrance of the CA
active site may accommodate both activators as well as inhibitors:
the difference between the two classes of modulators is that the
activators must incorporate protonatable moieties which may par-
ticipate in proton shuttling processes, similar to His64.
Thus, the designed CAAs reported here, 1–14, synthesized by
using histamine as lead, were investigated kinetically for their
interaction with the physiologically relevant isoforms hCA I and
II, (Table 1). Histamine (HST) has been used as a standard activator
in these experiments, although this compound is not a highly effec-
tive CAA (it has a KA of 2 lM against hCA I and of 125 lM against
hCA II).12b The following structure activity relationship (SAR) can
be evidenced from the activation data of Table 1:
(i) All synthesized compounds 1–14 showed effective hCA I
activating properties, with activation constants ranging
between 0.81 and 993 nM. Both mono-ureas (1–3) as well
as bis-derivatives (4–14) showed good such properties. For
this first subseries the SAR is quite straightforward, with
the butyl-derivative 1 being a low nanomolar activator (KA
of 6.1 nM), whereas the longer chain compounds showed a
progressive decreasing activity with the increase of the RN
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Scheme 2. CA-mediated hydrolysis of coumarin 15a to the 2-hydroxycinnamic acid
derivative 15b.17
Fig. 1. Binding of a hydrolyzed coumarin derivative (compound 15b, in yellow)17 to
the CA II active site (70), superposed with the CAAs L-adrenaline (magenta) and
histamine (blue sky): the coumarin and CAA binding sites are the same.12 The zinc
ion (violet sphere) and its three His ligands (His94, 96 and 119) as well as the
protein backbone (green ribbon) are also shown. His64, the proton shuttle residue
of the enzyme is represented in red.
Y. Le Duc et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 3from C4 to C18 (Table 1). For bis-derivatives 4–14, the SAR
seems to be more complex. Thus, for the compounds with
an alkyl linker 8and amino moieties), 4–7, activity is in theTable 1
Activation of human isozymes hCA I and II with compounds 1–14 by a stopped-flow CO2
No. Z, Y R R0
1 ANH2, H Butyl –
2 ANH2, H Hexyl –
3 ANH2, H Octadecyl –
4 ANH2, H – Butane-1,4-d
5 ANH2, H – Hexane-1,4-
6 ANH2, H – Octane-1,4-d
7 ANH2, H – Dodecane-1,
8 COOH, H – Hexane-1,4-
9 ANH2, H – 1,3,3-trimeth
10 ANH2, H – 1,4-phenylen
11 ANH2, H – 4-methyl-1,3
12 ANH2, H – Biphenyl-4,4
13 ANH2, H – 4,40-methyle
14 ANH2, H – 3,30-dimetho
Histamine – – –
a Errors in the range of ±5% of the reported data from three different assays.
Please cite this article in press as: Le Duc Y., et al. Bioorg. Med. Chem. (2017),11.1–982 nM range, with the best KA for the compounds
with a C8 linker (derivative 6). Thus, the activating proper-
ties increase from C4 to C6 and then to the C8-linker deriva-
tive, whereas a longer linker as in 7 (C12) leads to a strong
decrease of the CA activating properties. The compound
incorporating COOH instead of amino moieties as the hete-
rocyclic ring, 8, was also an effective hCA I activator (KA of
13.7 nM), comparable or even slightly better than the corre-
sponding derivative incorporating amino groups, 5. The
compound with a cycloalkyl linker, 9, was not very active
as a CAA, probably due to the rather bulky nature of the lin-
ker. However, some of the aromatic linkers present in
derivatives 10–144 led to highly effective CAAs against iso-
form hCA I, such as derivatives 11, 12 and 13 (KAs of 0.81–
4.2 nM, Table 1). Thus, the derivative with 1,4-phenylene
linker (10) was moderately active (KA of 65 nM) whereas
the one with the 1,3-phenylene linker, 11, had an increased
activity (KA of 4.2 nM). The biphenylene and methyl-biphe-
nylene linkers however were those which led to the best
hCA I activators, compounds 12 and 13, with activation con-
stants in the subnanomolar range. However the presence of
additional substituents at the biphenylene ring, as in 14, led
to a drastic reduction of the activating properties. Thus, for
this series of mono- or di-urea derivatives incorporating
1,2,4-triazole rings and amino/carboxy moieties as proton
transfer groups, activity was primarily influenced by the nat-
ure of the R moiety for the mono-ureas or the linker between
the two heterocyclic ring for the di-urea derivatives.
(ii) The physiologically dominant isoform hCA II was also effec-
tively activated by most derivatives investigated here, with
activation constants ranging between 0.05 and 6700 nM
(Table 1). SAR was rather similar with what mentioned
above for hCA II in the case of the mono-ureas 1–3, with
the best hCA II activator being the compound with the
shorter tail, 1 (KA of 1.7 nM) whereas activity progressively
decreased with the increase of the R length from C4 to
C18, in derivatives 2 and 3. For the bis-derivatives with alkyl
spacers, the best activity was observed for 5 (incorporating a
C6 linker) whereas the structurally related congeners with
shorter (4) or longer (6 and 7) linkers showed a similar acti-
vating profile, with activation constants of 65–91 nM. How-
ever, unlike the situation of hCA I, the carboxylic acid 8was a
very poor hCA II activator, with a KA of 6700 nM. The same
was true for the bis-amine 9, incorporating a cycloalkyl lin-
ker, with a KA of 1570 nM (Table 1). SAR was also ratherhydrase assay.18
KA (nM)a
hCA I hCA II
6.1 1.7
123 345
987 1680
iyl 74 91
diyl 42 14.6
iyl 11.1 65
4-diyl 982 79
diyl 13.7 6700
yl cyclohexyl)methyl 993 1570
e 65 0.12
-phenylene 4.2 826
0-diyl 0.81 14.1
nebis(1,4-phenylene) 0.94 0.05
xy biphenyl-4,40-diy 637 1680
2 lM 125 lM
http://dx.doi.org/10.1016/j.bmc.2017.01.031
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14. Thus 11, with a 1,4-phenylene linker was highly effective
as hCA II activator, with a KI of 0.12 nM, whereas the con-
gener with 1,3-phenylene linker lost activity being weakly
effective (KA of 826 nM). The activity was again good for
the biphenylene-linker derivative 12 (KA of 14.1 nM) and
excellent, probably the best hCA II activator ever reported,
for 13, with a methylene-biphenylene linker and a KA of
0.05 nM (Table 1). Additional moieties on the linker, such
as in 14, were again detrimental to the hCA II activating
properties.
(iii) The activating profile of these compounds for the two CA
isoforms were in general similar, although some compounds
do show some isoform selectivity. For example, 8 was hCA I
– selective as an activator, whereas 10 was rather hCA II –
selective. Compounds such as 1 or 13 were highly effective
activators of both isoforms.
3. Conclusions
In conclusion, in a small series of ureas/di-ureas incorporating
1,2,4-triazole substituted with amino or carboxyl groups as proton
shuttling moieties, highly efficient activators of the physiologically
relevant isoforms hCA I and II were evidenced. hCA I was activated
with activation constants ranging between 0.81 and 993 nM,
whereas hCA II with activation constants ranging between 0.05
and 6700 nM. The substitution pattern at the 1,2,4-triazole ring
and the nature of the linker between the two heterocyclic ring in
the case of the disubstituted compounds were the factors influenc-
ing the CA activating properties of these compounds. The most
effective hCA II activator (KA of 0.05 nM) ever reported has been
evidenced in this study. This may be relevant for finding clinical
candidates for investigating the role of CA activation in cognitive
impair or other diseases characterized by a CA I/II deficit, such as
Alzheimer’s disease or aging.
4. Experimental protocols
4.1. Chemistry
All compounds have been synthesized following the general
procedure described below. The amine (30 mmol) was mixed with
the corresponding amount of isocyanate, under sonication (1 eq.:
1 eq. for the monourea compounds and 2 eq.: 1 eq. for the bis-urea
compounds). The mixture was solubilized in 10 ml of THF (tetrahy-
drofuran), 5 ml of ethyl acetate, and 10 ml of dimethylacetamide.
The reaction mixture was heated to 120 C for 15 min. When the
precipitation begins 5 ml of acetonitrile are added and the heating
is maintained for another hour. The resulting product will be a
white powder which is then filtered and washed with methanol
on the filter paper. The exceptions of the protocol are compounds
1 and 4 for which the reaction temperature is 60 C and com-
pounds 2 and 5 for which the reaction temperature is 80 C. Com-
pound 1 is soluble in the reaction mixture and therefore the
purification procedure is as follows. The reaction mass is evapo-
rated under vacuum in a round bottomed flask and the compound
is then recrystallized from CHCl3. Alternatively a microwave reac-
tor has been used. The procedure is the following: the isocyanate
is dissolved in 5 ml of acetonitrile and added over the amine in
the microwave reactor. The reaction is performed at 140 C under
high stirring for 15 min. The product is then filtered and washed
with methanol. In the case of compounds 1a and 4 the temperature
is 50 C and for compounds 2 and 5 is 90 C. For compound 1 the
purification method is the same. All reagents were obtained fromPlease cite this article in press as: Le Duc Y., et al. Bioorg. Med. Chem. (2017),Aldrich and used without further purification. All organic solutions
were routinely dried by using sodium sulfate (Na2SO4). 1H and 13C
NMR spectra were recorded on an ARX 300 MHz Bruker spectrom-
eter in CDCl3 with the use of the residual solvent peak as reference.
3-Amino-N-butyl-1H-1,2,4-triazole-1-carboxamide, 1: 1H
NMR (DMSO-d6, 300 MHz) : d (ppm) = 0.89 (t, 3H, CH3CH2); 1.39
(h, 2H, CH3CH2CH2); 1.50 (qv, 2H, CH3CH2CH2); 3.19 (q, 2H,
CH2CH2NH); 7,15 (s, 2H, NH2); 7,48 (s, 1H, NCHN); 8.18 (t mod,1H,
NH).
3-Amino-N-hexyl-1H-1,2,4-triazole-1-carboxamide, 2: 1H
NMR (DMSO-d6, 300 MHz): d (ppm) = 0.86 (s, 3H, CH3CH2); 1.27
(m, 6H, CH2(CH2)3CH3); 1.51 (t, 2H, 2 J=6, 0 Hz, NHCH2CH2); 3.18
(q, 2J = 6.3 Hz, 2H, NHCH2CH2); 7.16 (s, 2H, NH2); 7.53 (s, 1H,
NCHN); 8.17 (s, 1H, NH); 13C-RMN (DMSO-d6, 75 MHz) : d (ppm)
= 13.85; 21.97; 25.84; 28.93; 30.87; 149.58; 150.91; 156.46.
3-Amino-N-octadecyl-1H-1,2,4-triazole-1-carboxamide, 3:
1H NMR (DMSO-d6, 300 MHz): d (ppm) = 0.85 (s, 3H, CH2CH3);
1.24–1.37 (m, 32H, CH2(CH2)16CH3); 2.94 (q, 2H, NHCH2CH2);
7.17 (s, 2H, NH2); 7.53 (s, 1H, NCHN); 8.22 (s, 1H, NH).
N,N0-(Butane-1,4-diyl)bis(3-amino-1H-1,2,4-triazole-1-car-
boxamide), 4: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 1.52 (s,
2H, NHCH2CH2); 3.20 (d, 2J = 5,4 Hz, 2H, NHCH2CH2); 7.17 (s, 2H,
NH2); 7.53 (s, 1H, CH); 8.24 (t, 2J = 5,4 Hz, 1H, NH) 13C-NMR
(DMSO-d6, 75 MHz): d (ppm) = 26.38; 149.60; 150.95; 156.47.
N,N0-(Hexane-1,6-diyl)bis(3-amino-1H-1,2,4-triazole-1-car-
boxamide), 5: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 1.29 (m,
4H, CH2(CH2)2CH2); 1.52 (t, 4H, 2J = 6.3 Hz, NHCH2CH2); 3.17 (q,
2J = 6.6 Hz, 4H, NHCH2CH2); 7.14 (br s, 4H, NH2); 7.52 (s, 1H,
NCHN); 8.17 (t, 2J = 6.6 Hz, 2H, NH) 13C-NMR (DMSO-d6, 75 MHz)
: d (ppm) = 25.85; 28.93; 149.58; 150.92; 156.46.
N,N0-(Octane-1,8-diyl)bis(3-amino-1H-1,2,4-triazole-1-car-
boxamide), 6: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 1.27 (s, 8H,
CH2(CH2)4CH2); 1.50 (m, 4H, 2J = 5.7 Hz, NHCH2CH2); 3.16 (q,
2J = 6.6 Hz, 4H, NHCH2CH2); 7.15 (s, 4H, NH2); 7.52 (s, 2H, NCHN);
8.18 (t, 2J = 6.0 Hz, 2H, NH) 13C-RMN (DMSO-d6, 75 MHz):
d (ppm) = 26.14; 28.56; 28.95; 149.59; 150.91; 156.46.
N,N0-(Dodecane-1,12-diyl)bis(3-amino-1H-1,2,4-triazole-1-
carboxamide), 7: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 1.24 (s,
16H, CH2(CH2)8CH2); 1.52 (m, 4H, 2J = 6.6 Hz, NHCH2CH2); 3.18 (q,
2J = 6.6 Hz, 4H, NHCH2CH2); 7.15 (s, 4H, NH2); 7.53 (s, 2H, NCHN);
8.17 (t, 2J = 6.6 Hz, 2H, NH). 13C-NMR (DMSO-d6, 75 MHz): d
(ppm) = 26.16; 28.62; 28.90; 28.94; 149.58; 150.91; 156.46.
1,10-(Hexane-1,6-diylbis(azanediyl))bis(oxomethylene)bis(1H-
1,2,4-triazole-3-carboxylic acid), 8: 1H NMR (DMSO-d6, 300 MHz):
d (ppm) = 1.31 (s, 4H, CH2(CH2)2CH2); 1.55 (m, 4H, 2J = 6.6 Hz,
NHCH2CH2); 3.24 (q, 2J = 6.6 Hz, 4H, NHCH2CH2); 8.26 (s, 2H,
NCHN); 8.73 (t, 2J = 6.6 Hz, 2H, NH); 9.11 (s, 1H, COOH). 13C-NMR
(DMSO-d6, 75 MHz) : d (ppm) = 23.32; 25.89; 29.15; 34.50;
37.79; 150.59; 151.20; 153.75; 154.,78; 155.57; 160.39; 160.39;
169.52.
3-Amino-N-((5-(3-amino-1H-1,2,4-triazole-1-carboxamido)-
1,3,3-trimethylcyclohexyl)methyl)-1H-1,2,4-triazole-1-carbox-
amide, 9: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 0.90 (s, 3H,
CH3); 1.02 (s, 6H, CH3); 1.13 (d, 2H, 2J = 8.1 Hz, NHCHCH2); 1.48
(s, 2H, CCH2C); 2.96 (t, 2H, 2J = 6.6 Hz, NHCH2); 2.96 (m, 2H,
2J = 6.6 Hz, NHCH2); 3.96 (m, 1H, NHCH); 7.17 (s, 4H, NH2); 7.52
(s, 1H, NCHN); 7.55 (s, 1H, NCHN); 7.92 (d, 2H, 2J = 8.4 Hz, NHCH);
7.98 (t, 2H, 2J = 6.6 Hz, NHCH2); 13C-NMR (DMSO-d6, 75 MHz): d
(ppm) = 23.27; 27.42; 31.45; 34.90; 36.68; 43.44; 44.39;
46.47; 52.60; 149.56; 149.68; 150.18; 151.40; 156.45; 156.57;
206.43.
N,N0-(1,4-Phenylene)bis(3-amino-1H-1,2,4-triazole-1-carbox-
amide), 10: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 5.83 (s, 4H,
NH2); 7.31 (s, 2H, NCHN); 8.30 (s, 2H, NHPh); 11.94 (s, 4H, HPh).http://dx.doi.org/10.1016/j.bmc.2017.01.031
Y. Le Duc et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 5N,N0-(4-Methyl-1,3-phenylene)bis(3-amino-1H-1,2,4-triazole-
1-carboxamide), 11: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 2.21
(s, 3H, CH3); 7.19–7.3 (m, 5H,(NH2)2 + HPh); 7.42 (s, 4H, HPh); 7.61
(m, 2H, NCHN + HPh); 7.65 (s, 1H, NCHN); 7.84 (s, 1H, CH); 9.65 (s,
1H, NH); 10.14 (s, 1H, NH).
N,N0-(Biphenyl-4,40-diyl)bis(3-amino-1H-1,2,4-triazole-1-car-
boxamide), 12: 1H NMR (DMSO-d6, 300 MHz): d (ppm) = 6.46 (d,
4H,2J = 3,9 Hz, HPh); 7.08 (d, 4H, 2J = 3,9 Hz, HPh); 7.32 (s, 4H,
NH2); 7.44 (s, 2H, NCHN); 7.49 (s, 2H, NHPh).
N,N0-(4,40-Methylenebis(4,1-phenylene))bis(3-amino-1H-1,2,4-
triazole-1-carboxamide), 13: 1H NMR (DMSO-d6, 300MHz): d
(ppm) = 3.89 (s, 4H,CH2); 7.19 (d, 2H, J = 12 Hz, HPh); 7.31 (s, 4H,
NH2); 7.62 (d, 2H, J = 12 Hz, HPh); 7.57 (s, 2H, NCHN); 10.05 (s, 2H,
NH).
N,N0-(3,30-Dimethoxybiphenyl-4,40-diyl)bis(3-amino-1H-1,2,4-
triazole-1-carboxamide), 14: 1H NMR (DMSO-d6, 300 MHz): d
(ppm) = 4.02 (s, 6H, CH3); 7.38–7.40 (m, 8H, NH2 + HPh); 7.67 (s,
6 = 2H, NCHN); 8.08 (d, 2H, J = 12, HPh); 9.34 (s, 2H, NH).
4.2. Carbonic anhydrase activation assay
An SX.18MV-R Applied Photophysics (Oxford, UK) stopped-flow
instrument has been used to assay the catalytic/inhibition of vari-
ous CA isozymes as reported by Khalifah.18 The CA-catalysed CO2
hydration reaction was followed for a period of 5–10 s. Phenol
red (at a concentration of 0.2 mM) was used as indicator, working
at the absorbance maximum of 557 nm, with 10 mM HEPES (pH
7.4) as buffer and 0.1 M NaClO4 for maintaining constant the ionic
strength (these anions are not inhibitory in the used concentra-
tion). Saturated CO2 solutions in water at 25 C were used as sub-
strates. Stock solutions of activators were prepared at a
concentration of 10 mM (in the assay buffer) and dilutions up to
0.01 nM done with the same assay buffer. Activator and enzyme
solutions were preincubated together for 15 min at room temper-
ature prior to assay, in order to allow for the formation of the
enzyme-activator complex. The activation constant (KA), defined
similarly with the inhibition constant KI,5–8 can be obtained by
considering the classical Michaelis-Menten equation (Eq. (1)),
which has been fitted by non-linear least squares by using
PRISM 3:
v ¼ vmax= 1þ KM=½Sð1þ ½Af=KAÞ
  ð1Þ
where [A]f is the free concentration of activator.
Working at substrate concentrations considerably lower than
KM ([S] KM), and considering that [A]f can be represented in
the form of the total concentration of the enzyme ([E]t) and activa-
tor ([A]t), the obtained competitive steady-state equation for deter-
mining the activation constant is given by Eq. (2):7–9
v ¼ v0  KA=fKA þ ð½At
 0:5fð½At þ ½Et þ KAÞ  ð½At þ ½Et þ KAÞ2  4½At  ½EtÞ1=2gg ð2Þ
where v0 represents the initial velocity of the enzyme-catalyzed
reaction in the absence of activator.12–15 The CA isoforms were
recombinant ones, and were prepared in-house as reported
earlier.19,20
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